<?xml version='1.0' encoding='UTF-8'?>
<extracted-tables-set><pmcid>8429427</pmcid><all-ids><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" pub-id-type="pmid">34504080</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" pub-id-type="pmc">8429427</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" pub-id-type="publisher-id">25492</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" pub-id-type="doi">10.1038/s41467-021-25492-9</article-id></all-ids><extracted-table><table-id>Tab1</table-id><table-label>Table 1</table-label><table-caption>Dataset characteristics.</table-caption><original-table><table-wrap xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" id="Tab1"><label>Table 1</label><caption><p>Dataset characteristics.</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="2">Cohorts</th><th>Training set</th><th>Validation set</th><th>Test set</th></tr></thead><tbody><tr><td rowspan="3">DIAN non-carriers</td><td><italic>N</italic></td><td>105</td><td rowspan="3">—</td><td>29</td></tr><tr><td>Age [range]</td><td>38.70 ± 11.41 [19–69]</td><td>38.90 ± 11.55 [20–58]</td></tr><tr><td>Sex ratio F/M [F]</td><td>57/48 [54%]</td><td>18/11 [62%]</td></tr><tr><td rowspan="3">DIAN carriers</td><td><italic>N</italic></td><td rowspan="3">—</td><td rowspan="3">—</td><td>125</td></tr><tr><td>Age [range]</td><td>34.33 ± 9.66 [18–61]</td></tr><tr><td>Sex ratio F/M [F]</td><td>68/57 [54%]</td></tr><tr><td rowspan="3">PREVENT-AD</td><td><italic>N</italic></td><td>36</td><td rowspan="3">—</td><td>256</td></tr><tr><td>Age [range]</td><td>63.5 ± 5.08 [55–78]</td><td>63.51 ± 5.37 [55–84]</td></tr><tr><td>Sex ratio F/M [F]</td><td>25/11 [69%]</td><td>189/67 [74%]</td></tr><tr><td rowspan="3">CamCAN</td><td><italic>N</italic></td><td>408</td><td rowspan="3">—</td><td>96</td></tr><tr><td>Age [range]</td><td>51.12 + 18.27 [18–87]</td><td>55.80 ± 19.30 [18–88]</td></tr><tr><td>Sex ratio F/M [F]</td><td>208/200 [51%]</td><td>40/56 [42%]</td></tr><tr><td rowspan="3">ADNI</td><td><italic>N</italic></td><td>29</td><td rowspan="3">—</td><td>15</td></tr><tr><td>Age [range]</td><td>76.41 ± 6.60 [66–94]</td><td>72.73 ± 6.70 [65–90]</td></tr><tr><td>Sex ratio F/M [F]</td><td>17/12 [59%]</td><td>10/5 [67%]</td></tr><tr><td rowspan="3">FCP-Cambridge</td><td><italic>N</italic></td><td>195</td><td rowspan="3">—</td><td rowspan="3">—</td></tr><tr><td>Age [range]</td><td>21.04 ± 2.33 [18–30]</td></tr><tr><td>Sex ratio F/M [F]</td><td>122/73 [63%]</td></tr><tr><td rowspan="3">ICBM</td><td><italic>N</italic></td><td rowspan="3">—</td><td>46</td><td rowspan="3">—</td></tr><tr><td>Age [range]</td><td>42.28 ± 19.31 [19–79]</td></tr><tr><td>Sex ratio F/M [F]</td><td>29/17 [63]</td></tr><tr><td rowspan="3">Total sample</td><td><italic>N</italic></td><td>773</td><td>46</td><td>521</td></tr><tr><td>Age [range]</td><td>43.37 ± 20.45 [18–94]</td><td>42.28 ± 19.31 [19–79]</td><td>54.49 ± 16.25 [18–90]</td></tr><tr><td>Sex ratio F/M [F]</td><td>429/344 [55%]</td><td>29/17 [63%]</td><td>325/196 [62%]</td></tr></tbody></table><table-wrap-foot><p>Demographic information by cohort and set.</p><p><italic>F</italic> Female, <italic>M</italic> male, <italic>DIAN</italic> Dominantly Inherited Alzheimer Network, <italic>PREVENT-AD</italic> Pre-symptomatic Evaluation of Experimental or Novel Treatments for Alzheimer’s Disease cohort, <italic>CamCAN</italic> Cambridge Centre for Ageing and Neuroscience, <italic>FCP-Cambridge</italic> 1000-Functional Connectomes Project—Cambridge site, <italic>ADNI</italic> Alzheimer’s Disease Neuroimaging Initiative, <italic>ICBM</italic> the International Consortium for Brain Mapping.</p></table-wrap-foot></table-wrap></original-table><transformed-table>Table 1<div xmlns="http://www.w3.org/1999/xhtml" class="caption">Dataset characteristics.</div><div xmlns="http://www.w3.org/1999/xhtml" class="table"><table frame="hsides" rules="groups"><thead><tr><th colspan="2">Cohorts</th><th>Training set</th><th>Validation set</th><th>Test set</th></tr></thead><tbody><tr><td rowspan="3">DIAN non-carriers</td><td>N</td><td>105</td><td rowspan="3">—</td><td>29</td></tr><tr><td>Age [range]</td><td>38.70 ± 11.41 [19–69]</td><td>38.90 ± 11.55 [20–58]</td></tr><tr><td>Sex ratio F/M [F]</td><td>57/48 [54%]</td><td>18/11 [62%]</td></tr><tr><td rowspan="3">DIAN carriers</td><td>N</td><td rowspan="3">—</td><td rowspan="3">—</td><td>125</td></tr><tr><td>Age [range]</td><td>34.33 ± 9.66 [18–61]</td></tr><tr><td>Sex ratio F/M [F]</td><td>68/57 [54%]</td></tr><tr><td rowspan="3">PREVENT-AD</td><td>N</td><td>36</td><td rowspan="3">—</td><td>256</td></tr><tr><td>Age [range]</td><td>63.5 ± 5.08 [55–78]</td><td>63.51 ± 5.37 [55–84]</td></tr><tr><td>Sex ratio F/M [F]</td><td>25/11 [69%]</td><td>189/67 [74%]</td></tr><tr><td rowspan="3">CamCAN</td><td>N</td><td>408</td><td rowspan="3">—</td><td>96</td></tr><tr><td>Age [range]</td><td>51.12 + 18.27 [18–87]</td><td>55.80 ± 19.30 [18–88]</td></tr><tr><td>Sex ratio F/M [F]</td><td>208/200 [51%]</td><td>40/56 [42%]</td></tr><tr><td rowspan="3">ADNI</td><td>N</td><td>29</td><td rowspan="3">—</td><td>15</td></tr><tr><td>Age [range]</td><td>76.41 ± 6.60 [66–94]</td><td>72.73 ± 6.70 [65–90]</td></tr><tr><td>Sex ratio F/M [F]</td><td>17/12 [59%]</td><td>10/5 [67%]</td></tr><tr><td rowspan="3">FCP-Cambridge</td><td>N</td><td>195</td><td rowspan="3">—</td><td rowspan="3">—</td></tr><tr><td>Age [range]</td><td>21.04 ± 2.33 [18–30]</td></tr><tr><td>Sex ratio F/M [F]</td><td>122/73 [63%]</td></tr><tr><td rowspan="3">ICBM</td><td>N</td><td rowspan="3">—</td><td>46</td><td rowspan="3">—</td></tr><tr><td>Age [range]</td><td>42.28 ± 19.31 [19–79]</td></tr><tr><td>Sex ratio F/M [F]</td><td>29/17 [63]</td></tr><tr><td rowspan="3">Total sample</td><td>N</td><td>773</td><td>46</td><td>521</td></tr><tr><td>Age [range]</td><td>43.37 ± 20.45 [18–94]</td><td>42.28 ± 19.31 [19–79]</td><td>54.49 ± 16.25 [18–90]</td></tr><tr><td>Sex ratio F/M [F]</td><td>429/344 [55%]</td><td>29/17 [63%]</td><td>325/196 [62%]</td></tr></tbody></table></div>Demographic information by cohort and set.F Female, M male, DIAN Dominantly Inherited Alzheimer Network, PREVENT-AD Pre-symptomatic Evaluation of Experimental or Novel Treatments for Alzheimer’s Disease cohort, CamCAN Cambridge Centre for Ageing and Neuroscience, FCP-Cambridge 1000-Functional Connectomes Project—Cambridge site, ADNI Alzheimer’s Disease Neuroimaging Initiative, ICBM the International Consortium for Brain Mapping.</transformed-table></extracted-table><extracted-table><table-id>Tab2</table-id><table-label>Table 2</table-label><table-caption>DIAN and PREVENT-AD test set characteristics.</table-caption><original-table><table-wrap xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" id="Tab2"><label>Table 2</label><caption><p>DIAN and PREVENT-AD test set characteristics.</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>DIAN mutation non-carriers</th><th>DIAN mutation carriers</th><th>PREVENT-AD</th></tr></thead><tbody><tr><td><italic>N</italic></td><td align="left">29</td><td align="left">125</td><td align="left">256</td></tr><tr><td>Chronological Age (years; mean ± SD)</td><td>38.90 (±11.55)</td><td>34.33 (±9.66)</td><td>63.51 (±5.37)</td></tr><tr><td>Sex Ratio F/M (%)</td><td>18/11 (62%/38%)</td><td>68/57 (54%/46%)</td><td>189/67 (74%/26%)</td></tr><tr><td>Education (years; mean ± SD)</td><td>14.41 (2.13)</td><td>14.89 (±3.10)</td><td>15.65 (±3.51)</td></tr><tr><td>EYO (years; mean ± SD)<sup>a</sup></td><td>−8.56 (±10.85)</td><td>−14.18 (±8.94)</td><td>−10.42 (±7.21)</td></tr><tr><td><italic>APOE4</italic> carriers (%)<sup>b</sup></td><td>11 (38%)</td><td>36 (29%)</td><td>108 (42%)</td></tr><tr><td>Aβ-positive (%)<sup>c</sup></td><td>0 (0%)</td><td>39 (34%)</td><td>14 (22%)</td></tr><tr><td>MMSE or MoCA (mean ± SD)<sup>d</sup></td><td>29.36 ± 1.03</td><td>29.02 ± 1.27</td><td>28.11 ± 1.52</td></tr></tbody></table><table-wrap-foot><p><italic>Aβ</italic> beta-amyloid, <italic>Aβ</italic>− amyloid-negative, <italic>Aβ+</italic> amyloid-positive; <italic>APOE</italic> apolipoprotein E, <italic>EYO</italic> Estimated Years to Symptom Onset, <italic>MMSE</italic> Mini–Mental State Examination, <italic>MoCA</italic> Montreal Cognitive Assessment, <italic>SD</italic> standard deviation.</p><p><sup>a</sup>EYO in DIAN was calculated based on the parental age at onset. EYO of PREVENT-AD was calculated only for individuals with a parental history of AD, data was available for 241 participants.</p><p><sup>b</sup><italic>APOE</italic> genotyping was missing for 1 PREVENT-AD participant.</p><p><sup>c</sup>Aβ-PET data was missing for 2 mutation non-carriers and 11 mutation carriers in DIAN and 192 PREVENT-AD participants.</p><p><sup>d</sup>Global cognitive functioning was assessed using MMSE in DIAN and MoCA in PREVENT-AD.</p></table-wrap-foot></table-wrap></original-table><transformed-table>Table 2<div xmlns="http://www.w3.org/1999/xhtml" class="caption">DIAN and PREVENT-AD test set characteristics.</div><div xmlns="http://www.w3.org/1999/xhtml" class="table"><table frame="hsides" rules="groups"><thead><tr><th/><th>DIAN mutation non-carriers</th><th>DIAN mutation carriers</th><th>PREVENT-AD</th></tr></thead><tbody><tr><td>N</td><td align="left">29</td><td align="left">125</td><td align="left">256</td></tr><tr><td>Chronological Age (years; mean ± SD)</td><td>38.90 (±11.55)</td><td>34.33 (±9.66)</td><td>63.51 (±5.37)</td></tr><tr><td>Sex Ratio F/M (%)</td><td>18/11 (62%/38%)</td><td>68/57 (54%/46%)</td><td>189/67 (74%/26%)</td></tr><tr><td>Education (years; mean ± SD)</td><td>14.41 (2.13)</td><td>14.89 (±3.10)</td><td>15.65 (±3.51)</td></tr><tr><td>EYO (years; mean ± SD)a</td><td>−8.56 (±10.85)</td><td>−14.18 (±8.94)</td><td>−10.42 (±7.21)</td></tr><tr><td>APOE4 carriers (%)b</td><td>11 (38%)</td><td>36 (29%)</td><td>108 (42%)</td></tr><tr><td>Aβ-positive (%)c</td><td>0 (0%)</td><td>39 (34%)</td><td>14 (22%)</td></tr><tr><td>MMSE or MoCA (mean ± SD)d</td><td>29.36 ± 1.03</td><td>29.02 ± 1.27</td><td>28.11 ± 1.52</td></tr></tbody></table></div>Aβ beta-amyloid, Aβ− amyloid-negative, Aβ+ amyloid-positive; APOE apolipoprotein E, EYO Estimated Years to Symptom Onset, MMSE Mini–Mental State Examination, MoCA Montreal Cognitive Assessment, SD standard deviation.aEYO in DIAN was calculated based on the parental age at onset. EYO of PREVENT-AD was calculated only for individuals with a parental history of AD, data was available for 241 participants.bAPOE genotyping was missing for 1 PREVENT-AD participant.cAβ-PET data was missing for 2 mutation non-carriers and 11 mutation carriers in DIAN and 192 PREVENT-AD participants.dGlobal cognitive functioning was assessed using MMSE in DIAN and MoCA in PREVENT-AD.</transformed-table></extracted-table><extracted-table><table-id>Tab3</table-id><table-label>Table 3</table-label><table-caption>Model’s prediction according to the presence of genetic mutation/risk and Aβ pathology in DIAN and PREVENT-AD cohorts (test set only).</table-caption><original-table><table-wrap xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" id="Tab3"><label>Table 3</label><caption><p>Model’s prediction according to the presence of genetic mutation/risk and Aβ pathology in DIAN and PREVENT-AD cohorts (test set only).</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2"/><th colspan="5">DIAN</th><th colspan="4">PREVENT-AD</th></tr><tr><th>Mutation NonCarriers</th><th>Mutation Carriers</th><th>Mutation NonCarriers Aβ−</th><th>Mutation Carriers Aβ−</th><th>Mutation Carriers Aβ+</th><th><italic>APOE4</italic> NonCarriers</th><th><italic>APOE4</italic> Carriers</th><th>Aβ−</th><th>Aβ+</th></tr></thead><tbody><tr><td><italic>N</italic></td><td>29</td><td>125</td><td>29<sup>a</sup></td><td>75</td><td>39</td><td>147</td><td>108</td><td>50</td><td>14</td></tr><tr><td>Chronological Age in years (±SD)</td><td>38.90 (±11.55)</td><td>34.35<sup>b</sup> (±9.66)</td><td>38.90 (±11.55)</td><td>33.15<sup>b</sup> (±9.09)</td><td>38.18<sup>b</sup> (±10.04)</td><td>63.89 (±5.74)</td><td>63.05 (±4.77)</td><td>62.90 (±4.28)</td><td>64.71 (±5.69)</td></tr><tr><td>Predicted Age in years (±SD)</td><td>35.35 (±12.90)</td><td>42.51<sup>b</sup> (±13.90)</td><td>35.35 (±12.90)</td><td>41.55<sup>b</sup> (±13.19)</td><td>41.18<sup>b</sup> (±14.09)</td><td>68.94 (±5.14)</td><td>68.46 (±5.01)</td><td>68.80 (±6.08)</td><td>70.37 (±2.97)</td></tr><tr><td>PAD in years (±SD)</td><td>−3.54 (±18.99)</td><td>8.19<sup>b</sup> (±17.63)</td><td>−3.54 (±18.99)</td><td>8.40<sup>b</sup> (±17.21)</td><td>6.62<sup>b</sup> (±18.09)</td><td>5.04 (±7.62)</td><td>5.41 (±6.79)</td><td>5.90 (±7.60)</td><td>5.66 (±6.56)</td></tr></tbody></table><table-wrap-foot><p><italic>Aβ−</italic> amyloid-negative, <italic>Aβ+</italic> amyloid-positive, <italic>PAD</italic> predicted age difference, <italic>SD</italic> standard deviation.</p><p><sup>a</sup>Aβ-PET data was missing for 2 mutation non-carriers. To avoid further reducing the number of individuals in this group, they were both exceptionally kept for the corresponding analysis and their Aβ negativity was determined based on (i) their CSF data (available for both of them) and (ii) the unlikelihood that they have detectable Aβ pathology on PET considering their young age and the absence of ADAD mutation.</p><p><sup>b</sup>indicates a significant difference from DIAN mutation noncarriers (<italic>p</italic> &lt; .05); of note, no differences were found between DIAN mutation carriers Aβ− and DIAN mutation carriers Aβ+, neither in PREVENT-AD when comparing <italic>APOE4</italic> noncarriers to <italic>APOE4</italic> carriers or Aβ− to Aβ+. Statistical values were obtained using general linear models, including group as a predictor, without adjustment (two-sided).</p></table-wrap-foot></table-wrap></original-table><transformed-table>Table 3<div xmlns="http://www.w3.org/1999/xhtml" class="caption">Model’s prediction according to the presence of genetic mutation/risk and Aβ pathology in DIAN and PREVENT-AD cohorts (test set only).</div><div xmlns="http://www.w3.org/1999/xhtml" class="table"><table frame="hsides" rules="groups"><thead><tr><th rowspan="2"/><th colspan="5">DIAN</th><th colspan="4">PREVENT-AD</th></tr><tr><th>Mutation NonCarriers</th><th>Mutation Carriers</th><th>Mutation NonCarriers Aβ−</th><th>Mutation Carriers Aβ−</th><th>Mutation Carriers Aβ+</th><th>APOE4 NonCarriers</th><th>APOE4 Carriers</th><th>Aβ−</th><th>Aβ+</th></tr></thead><tbody><tr><td>N</td><td>29</td><td>125</td><td>29a</td><td>75</td><td>39</td><td>147</td><td>108</td><td>50</td><td>14</td></tr><tr><td>Chronological Age in years (±SD)</td><td>38.90 (±11.55)</td><td>34.35b (±9.66)</td><td>38.90 (±11.55)</td><td>33.15b (±9.09)</td><td>38.18b (±10.04)</td><td>63.89 (±5.74)</td><td>63.05 (±4.77)</td><td>62.90 (±4.28)</td><td>64.71 (±5.69)</td></tr><tr><td>Predicted Age in years (±SD)</td><td>35.35 (±12.90)</td><td>42.51b (±13.90)</td><td>35.35 (±12.90)</td><td>41.55b (±13.19)</td><td>41.18b (±14.09)</td><td>68.94 (±5.14)</td><td>68.46 (±5.01)</td><td>68.80 (±6.08)</td><td>70.37 (±2.97)</td></tr><tr><td>PAD in years (±SD)</td><td>−3.54 (±18.99)</td><td>8.19b (±17.63)</td><td>−3.54 (±18.99)</td><td>8.40b (±17.21)</td><td>6.62b (±18.09)</td><td>5.04 (±7.62)</td><td>5.41 (±6.79)</td><td>5.90 (±7.60)</td><td>5.66 (±6.56)</td></tr></tbody></table></div>Aβ− amyloid-negative, Aβ+ amyloid-positive, PAD predicted age difference, SD standard deviation.aAβ-PET data was missing for 2 mutation non-carriers. To avoid further reducing the number of individuals in this group, they were both exceptionally kept for the corresponding analysis and their Aβ negativity was determined based on (i) their CSF data (available for both of them) and (ii) the unlikelihood that they have detectable Aβ pathology on PET considering their young age and the absence of ADAD mutation.bindicates a significant difference from DIAN mutation noncarriers (p &lt; .05); of note, no differences were found between DIAN mutation carriers Aβ− and DIAN mutation carriers Aβ+, neither in PREVENT-AD when comparing APOE4 noncarriers to APOE4 carriers or Aβ− to Aβ+. Statistical values were obtained using general linear models, including group as a predictor, without adjustment (two-sided).</transformed-table></extracted-table></extracted-tables-set>